ArticleAdvances in therapy2023

Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Resected Stage IIB or IIC Melanoma in the United States.

Shujing Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.